Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 44.89M | 41.68M | 40.66M | 40.21M | 38.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.89M | 41.68M | 40.66M | 40.21M | 38.26M |
| Cost of Revenue | 17.75M | 17.08M | 16.66M | 16.31M | 15.48M |
| Gross Profit | 27.14M | 24.59M | 24.00M | 23.90M | 22.78M |
| SG&A Expenses | 20.13M | 19.35M | 19.82M | 19.59M | 19.43M |
| Depreciation & Amortization | 27.00K | 226.00K | 544.00K | 862.00K | 1.15M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.54M | 37.24M | 37.65M | 37.40M | 36.63M |
| Operating Income | 6.36M | 4.44M | 3.01M | 2.81M | 1.63M |
| Income Before Tax | 4.90M | 3.01M | 1.27M | 1.13M | -1.09M |
| Income Tax Expenses | 17.00K | 17.00K | 17.00K | 17.00K | 17.00K |
| Earnings from Continuing Operations | 4.89 | 3.00 | 1.25 | 1.11 | -1.11 |
| Earnings from Discontinued Operations | -185.00K | -189.00K | -335.00K | -310.00K | -542.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.70M | 2.81M | 919.00K | 802.00K | -1.65M |
| EBIT | 6.36M | 4.44M | 3.01M | 2.81M | 1.63M |
| EBITDA | 6.63M | 4.87M | 3.73M | 3.84M | 2.94M |
| EPS Basic | 1.08 | 0.64 | 0.21 | 0.19 | -0.39 |
| Normalized Basic EPS | 0.70 | 0.43 | 0.18 | 0.16 | -0.15 |
| EPS Diluted | 1.07 | 0.63 | 0.20 | 0.18 | -0.39 |
| Normalized Diluted EPS | 0.70 | 0.43 | 0.18 | 0.16 | -0.15 |
| Average Basic Shares Outstanding | 17.47M | 17.40M | 17.33M | 17.27M | 17.21M |
| Average Diluted Shares Outstanding | 17.55M | 17.44M | 17.36M | 17.28M | 17.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
